PT  - JOURNAL ARTICLE
AU  - Christensen, Paul A.
AU  - Olsen, Randall J.
AU  - Long, S. Wesley
AU  - Snehal, Richard
AU  - Davis, James J.
AU  - Saavedra, Matthew Ojeda
AU  - Reppond, Kristina
AU  - Shyer, Madison N.
AU  - Cambric, Jessica
AU  - Gadd, Ryan
AU  - Thakur, Rashi M.
AU  - Batajoo, Akanksha
AU  - Mangham, Regan
AU  - Pena, Sindy
AU  - Trinh, Trina
AU  - Kinskey, Jacob C.
AU  - Williams, Guy
AU  - Olson, Robert
AU  - Gollihar, Jimmy
AU  - Musser, James M.
TI  - Signals of significantly increased vaccine breakthrough, decreased hospitalization rates, and less severe disease in patients with COVID-19 caused by the Omicron variant of SARS-CoV-2 in Houston, Texas
AID  - 10.1101/2021.12.30.21268560
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2021.12.30.21268560
4099  - http://medrxiv.org/content/early/2022/01/19/2021.12.30.21268560.short
4100  - http://medrxiv.org/content/early/2022/01/19/2021.12.30.21268560.full
AB  - Genetic variants of SARS-CoV-2 continue to dramatically alter the landscape of the COVID-19 pandemic. The recently described variant of concern designated Omicron (B.1.1.529) has rapidly spread worldwide and is now responsible for the majority of COVID-19 cases in many countries. Because Omicron was recognized very recently, many knowledge gaps exist about its epidemiology, clinical severity, and disease course. A genome sequencing study of SARS-CoV-2 in the Houston Methodist healthcare system identified 4,468 symptomatic patients with infections caused by Omicron from late November 2021 through January 5, 2022. Omicron very rapidly increased in only three weeks to cause 90% of all new COVID-19 cases, and at the end of the study period caused 98% of new cases. Compared to patients infected with either Alpha or Delta variants in our healthcare system, Omicron patients were significantly younger, had significantly increased vaccine breakthrough rates, and were significantly less likely to be hospitalized. Omicron patients required less intense respiratory support and had a shorter length of hospital stay, consistent with on average decreased disease severity. Two patients with Omicron “stealth” sublineage BA.2 also were identified. The data document the unusually rapid spread and increased occurrence of COVID-19 caused by the Omicron variant in metropolitan Houston, and address the lack of information about disease character among US patients.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis project was supported by the Houston Methodist Academic Institute Infectious Diseases Fund; and supported in whole or in part with federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract No. 75N93019C00076 (J.J.D. and R.O.).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This work was approved by the Houston Methodist Research institutional review board (IRB1010-0199).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesGenome data used in this study have been deposited to GISAID. https://www.gisaid.org